These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21080211)

  • 1. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
    Schmidt-Hieber M; Dabrowski R; Weimann A; Aicher B; Lohneis P; Busse A; Thiel E; Blau IW
    Invest New Drugs; 2012 Apr; 30(2):480-9. PubMed ID: 21080211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
    Schmidt-Hieber M; Dabrowski R; Aicher B; Lohneis P; Busse A; Tietze-Buerger C; Reufi B; Thiel E; Blau IW
    Invest New Drugs; 2012 Aug; 30(4):1396-403. PubMed ID: 21750922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
    Rushworth SA; Bowles KM; Barrera LN; Murray MY; Zaitseva L; MacEwan DJ
    Cell Signal; 2013 Jan; 25(1):106-12. PubMed ID: 22975686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
    Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
    Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
    Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
    Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
    Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
    Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
    Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
    Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
    Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.
    Reis-Sobreiro M; Gajate C; Mollinedo F
    Oncogene; 2009 Sep; 28(36):3221-34. PubMed ID: 19561642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Ciccarelli B; Richardson PG; Palladino MA; Anderson KC
    Blood; 2010 Jan; 115(4):834-45. PubMed ID: 19965674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
    Hideshima T; Catley L; Yasui H; Ishitsuka K; Raje N; Mitsiades C; Podar K; Munshi NC; Chauhan D; Richardson PG; Anderson KC
    Blood; 2006 May; 107(10):4053-62. PubMed ID: 16418332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
    Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
    Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J; Koyama D; Mukai HY; Furukawa Y
    Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
    Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
    Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
    Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.